Local Anesthesia for TAVR Was Safe and Reduced Hospital Stays

A minimalist approach to transcatheter aortic valve replacement (TAVR) involving local anesthesia appears to have several advantages, according to this new meta-analysis.

 

In addition to shortening times for procedures and lengths of stay in the critical care unit and hospital, lighter sedation may lower the need for transfusions or treatment with inotropes or vasopressors.

 

Those benefits do not come with clinical complications. In fact, mortality at 30 days was lower in those receiving TAVR with local anesthesia (3.7% vs. 4.2%; risk ratio [RR]: 0.76; 95% confidence interval [CI]: 0.64-0.92).

 

In the earlier days of TAVR, procedures were typically performed under general anesthesia with orotracheal intubation. However, in time, accumulating evidence suggested that using local anesthesia in the procedure, as part of a minimalist approach, is not only feasible but also beneficial.

 

While the meta-analysis is not to be considered as definitive evidence as regards hard endpoints such as mortality, a minimalist strategy presents enough advantages to support its application.

 

This meta-analysis included 27 studies and a total of 24,085 patients.

 

Most procedural variables turned out to be similar for both strategies, including rates of stroke, acute myocardial infarction, renal failure, vascular complications, major bleeding, a need for a permanent pacemaker, paravalvular insufficiency, or fluoroscopy time.

 

Patients who received local anesthesia presented the following advantages:

  • a shorter average procedure time (90 vs. 127 minutes),
  • less time in the critical care unit (1.5 vs. 3.0 days),
  • less time in the hospital (5 vs 9 days),
  • possibly, lower mortality (although this conclusion might be biased).

 

Original title: Comparison of Local Versus General Anesthesia in Patients Undergoing Transcatheter Aortic Valve Replacement: A Meta-Analysis and Meta-Regression.

Presenter: Villablanca PA.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

Cardiac Remodeling After Percutaneous ASD Closure: Should It Be Immediate or Progressive?

Atrial septal defect (ASD) is a common congenital heart disease that generates a left-to-right shunt, leading to right-side chamber overload and a risk of...

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

Is it really necessary to monitor all patients after TAVR?

Conduction disorders (CD) after transcatheter aortic valve replacement (TAVR) are a frequent complication and may lead to the need for permanent pacemaker implantation (PPI)....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...